Nivolumab a-k-a OPDIVO is a FDA-approved checkpoint inhibitor drug for the treatment of a subset of cancer types. It is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Nivolumab is an IgG4 kappa immunoglobulin that has a calculated molecular mass of 146 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line. Indication of Nivolumab Immunotherapy Nivolumab (OPDIVO) is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of: Patients with BRAF V600 wild-type unresectable or metastatic melanoma, as a single agent. Patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, as a single agent. Patients with unresectable or metastatic melanoma, in combination with ipilimumab. Patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting. Patients with meta...